Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09FMK
|
|||
| Former ID |
DNC004939
|
|||
| Drug Name |
AM-630
|
|||
| Synonyms |
164178-33-0; AM630; AM-630; iodopravadoline; (6-iodo-2-methyl-1-(2-morpholinoethyl)-1H-indol-3-yl)(4-methoxyphenyl)methanone; AM 630; UNII-U1LNJ6NBKA; U1LNJ6NBKA; CHEMBL181633; [6-iodo-2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]-(4-methoxyphenyl)methanone; 6-iodopravadoline; 1-(2-(Morpholin-4-yl)ethyl)-2-methyl-3-(4-methoxybenzoyl)-6-iodoindole; 1-[2-(morpholin-4-yl)ethyl]-2-methyl-3-(4-methoxybenzoyl)-6-iodoindole; Tocris-1120; AC1N7ICI; Iodopravadoline(AM-630); Iodopravadoline (AM630); GTPL750; MLS006010265
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H25IN2O3
|
|||
| Canonical SMILES |
CC1=C(C2=C(N1CCN3CCOCC3)C=C(C=C2)I)C(=O)C4=CC=C(C=C4)OC
|
|||
| InChI |
1S/C23H25IN2O3/c1-16-22(23(27)17-3-6-19(28-2)7-4-17)20-8-5-18(24)15-21(20)26(16)10-9-25-11-13-29-14-12-25/h3-8,15H,9-14H2,1-2H3
|
|||
| InChIKey |
JHOTYHDSLIUKCJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 164178-33-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6319093, 7978679, 9633965, 11113929, 14835756, 35590692, 53787323, 57356907, 74936685, 85209557, 85787595, 91746245, 103445420, 104046922, 104253200, 112831395, 134342144, 135315120, 135649929, 135698378, 136368110, 137125126, 140908945, 144115586, 152258712, 152344478, 160647548, 160813319, 162022994, 162108975, 162111840, 162191100, 162220118, 162476483, 163374446, 163837880, 174007487, 185998781, 204432375, 223393074, 223592620, 223704294, 228646821, 241182146, 242059741, 248761352, 249823045, 249967165, 252059225, 252160266
|
|||
| ChEBI ID |
CHEBI:93112
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Inhibitor | [2] |
| Cannabinoid receptor 2 (CB2) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Rap1 signaling pathway | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| BDNF signaling pathway | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 750). | |||
| REF 2 | New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6505-10. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.